FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7, 2017 – The FDA has placed partial clinical holds on 3 trials assessing nivolumab-based combinations in patients with relapsed/refractory multiple myeloma. The phase III CheckMate-602, phase I CheckMate-039, and phase II CA204142 are affected by the decision. Enrolled patients who are experiencing clinical benefit can continue treatment, but no new patients will be allowed to join the trials for the time being. In a press release, Bristol-Myers Squibb … (leggi tutto)